<DOC>
	<DOCNO>NCT00002206</DOCNO>
	<brief_summary>The purpose study see safe effective give adefovir dipivoxil day 4 week HIV-infected patient never treat anti-HIV medicine . This study also examine body process adefovir dipivoxil .</brief_summary>
	<brief_title>A Study Adefovir Dipivoxil HIV-Infected Patients Who Have Not Been Treated With Anti-HIV Drugs</brief_title>
	<detailed_description>This double-blind , placebo-controlled , randomized Phase I/II study safety , tolerance , pharmacokinetics , anti-HIV activity adefovir dipivoxil HIV-infected patient naive antiretroviral therapy . Patients randomize receive single daily dose adefovir dipivoxil match placebo tablet 4 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV infection , indicate history seropositivity HIV1 infection ( ELISA confirm Western blot ) . Peripheral blood CD4 cell count great equal 150 cells/mm3 least 1 measurement within 28 day prior enrollment . Plasma HIV1 RNA great equal 5,000 copies/ml within 28 day study entry . A minimum life expectancy 12 month . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active , serious infection ( HIV infection ) require parenteral antibiotic therapy . Patients consider recover infectious episode least 2 week elapse follow cessation parenteral antibiotic therapy . Evidence gastrointestinal malabsorption syndrome inability receive orallyadministered medication . A malignancy cutaneous Kaposi 's sarcoma ( KS ) . ( NOTE : Patients biopsyconfirmed KS eligible , must receive systemic therapy ( include chemotherapy ) KS within 4 week prior study entry . 1 . Antiretroviral therapy , include nucleoside analogue , nonnucleoside reverse transcriptase inhibitor , protease inhibitor , investigational antiretroviral agent ( antiretroviral therapy may start completion Day 35 followup visit ) . Interferon ( alpha , beta , gamma ) interleukin ( e.g. , IL2 ) . Aminoglycoside antibiotic , amphotericin B , cidofovir , diuretic , foscarnet , ganciclovir , itraconazole , fluconazole , ketoconazole ( topical allow ) , isoniazid , rifampin , rifabutin , clarithromycin , azithromycin , chemotherapeutic agent ( systemic ) , systemic corticosteroid , agent significant nephrotoxic potential , agent inhibit compete elimination via active renal tubular secretion ( e.g. , probenecid ) , investigational agent . 1 . Treatment HIV protease inhibitor . Treatment total 2 week nucleoside nonnucleoside reverse transcriptase inhibitor antiretroviral agent . Ongoing treatment interferon ( alpha , beta , gamma ) , interleukins immunomodulatory agent , systemic corticosteroid , investigational agent except sponsor 's approval within 1 month prior study entry . Evidence active substance abuse ( include alcohol ) , determine investigator , would preclude adequate compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 1999</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Adenine</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>